Navigation Links
United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
Date:2/26/2013

SILVER SPRING, Md., Feb. 26, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2012.

"Our excellent annual results reflect both our leadership in pulmonary hypertension medicines and our discipline in focusing company resources on transformative growth opportunities," noted Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "It is especially noteworthy that our medicines are now being prescribed to more pulmonary hypertension patients in the United States than any other company's medicines."

Total revenues for the quarter ended December 31, 2012 were $243.8 million, up from $195.2 million for the quarter ended December 31, 2011. Net income for the quarter ended December 31, 2012 was $83.3 million or $1.65 per basic share, compared to $43.2 million or $0.79 per basic share for the quarter ended December 31, 2011. For the year ended December 31, 2012, we had net income of $304.4 million, or $5.84 per basic share and $5.71 per diluted share, compared to $217.9 million, or $3.81 per basic share and $3.67 per diluted share, for the year ended December 31, 2011. Earnings before non-cash charges(1) for the quarter ended December 31, 2012, were $126.3 million or $2.50 per basic share, compared to $87.5 million or $1.61 per basic share for the quarter ended December 31, 2011.

(1)See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.  

Operating ResultsRevenues

The table below summarizes the components of revenues (in thousands): 

 Three Months EndedDecember 31,Year EndedDecember 31,2012201120122011Cardiop
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
2. United BioSource Corp. erweitert mit entscheidender Neubesetzung Potenzial in Europa
3. United BioSource Corp. expande sus capacidades europeas con contrataciones clave
4. United Kingdom Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
5. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
6. Kevin Johnson Joins United Allergy Services Board Of Directors
7. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
8. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
9. Virtual Ports Receives Patent Approvals in the United States and Japan
10. United States Hospital Supplies Market Outlook to 2018 - Disposable Hospital Supplies, Mobility Aids and Transportation Equipment, Operating Room Equipment, Sterilization and Disinfectant Equipment and Others
11. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... An article published August 19th by the LA Times ... to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza ... the current process, having already gone on for over a year, is taking much ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... 1, WASHINGTON, May 1 U.S. Paralympian April ... on the track. In September, she,will travel to Beijing ... favored to medal in the 100- and 200-meter dashes. ... well what working,Americans need to do to keep their ...
... notes, "We make,decisions for the right reasons and then we ... the right time, by the right people, and at the,right ... Management has now grown so much that an increasingly,sophisticated system ... and strategic at its core -- but that is fraught ...
... ... HILLS, Ill. and CORPUS CHRISTI, Texas, May 1 ... from Texas,A&M-Corpus Christi,s Kinesiology Department demonstrated the correlation,between improved ... improvement in the hitting performance of,Islander baseball players after ...
... Texas Cardiac Arrhythmia Recruits and Hires Dr. Andrea ... Executive Medical Director of the Texas Cardiac Arrhythmia,Institute ... May 1 St. David,s HealthCare,along with Texas ... Cardiac Arrhythmia Institute (TCAI) at St. David,s Medical ...
... N.C., May 1 The Oregon State,Supreme Court ... statewide class,action in which plaintiff sought to make ... for medical monitoring of all Oregon,cigarette smokers., ... of the complaint and,the intermediate appellate court,s unanimous ...
... hinder a protein called IGF-1 not entirely successful, studies ... idea that prostate cancer can be treated successfully just ... growth factor (IGF-1) has been undermined by two new ... by a number of drug companies and academic researchers, ...
Cached Medicine News:Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 2Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 3Health News:U.S. Paralympian April Holmes Teams With LIFE Foundation to Encourage Americans to Assess Their Disability Insurance Needs This May 4Health News:Best Practices in Designing Effective Brand Teams 2Health News:Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 2Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 3Health News:St. David's HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders 4Health News:Complications Found in Proposed Prostate Cancer Treatment 2
Bipolar Atrial "J" Lead...
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: